Company: BGLC
Filing Date: 2025-08-18
Form Type: 10-Q
Source: 0001477932-25-006023
Chunk: 50

Company: BioNexus Gene Lab Corp
Filing Date: 2025-08-18
Form: 10-Q
Item: Part I, Item 1
Chunk 50
---
 $4,397,328  $4,356,415                  COST OF REVENUE  (1,892,231)  (1,685,844)  (3,685,813)  (3,702,664)                 GROSS PROFIT  368,022   288,720   711,515   653,751                  OTHER INCOME                Dividend income   8,626   11,881   17,560   20,827 Interest income  29,768   49,739   53,336   78,722 Fair value gain on investments in equity securities  23,742   88,532   28,256   173,317 Gain on disposal of investments in equity securities  -   8,117   -   14,298 Reversal of expected credit losses  69,759   552,663   94,912   584,415 Others  77,566   19,173   106,817   60,373 TOTAL OTHER INCOME  209,461   730,105   300,881   931,952                  OPERATING EXPENSES                Sales and marketing  (608,427)  (136,494)  (1,149,122)  (290,365)Research and development  (12,557)  (8,198)  (24,696)  (19,673)General and administrative  (516,790)  (558,829)  (908,666)  (874,623)Fair value loss on investments in equity securities  (51,002)  (56,136)  (119,499)  (100,433)Provision for expected credit losses   -   -   (40,124)  (120,469)TOTAL OPERATING EXPENSES  (1,188,776)  (759,657)  (2,242,107)  (1,405,563)                 (LOSS)/PROFIT FROM OPERATIONS  (611,293)  259,168   (1,229,